Opportunistic pneumonia caused by Pneumocystis jirovecii in HIV/AIDS and other immunocompromised hosts; presents with dyspnea, dry cough, and hypoxia.
Also known as: PCP, PJP, Pneumocystis pneumonia, Pneumocystis carinii pneumonia, Pneumocystis jirovecii
Overview
Opportunistic pulmonary infection caused by the fungus Pneumocystis jirovecii (formerly Pneumocystis carinii). Hallmark of advanced HIV/AIDS but also affects other immunocompromised patients including solid organ transplant recipients, patients on chronic corticosteroids, and those receiving immunosuppressive chemotherapy.
Epidemiology
Most cases in HIV-infected patients with CD4 <200 cells/microL. Incidence in HIV has declined dramatically with antiretroviral therapy and TMP-SMX prophylaxis. In non-HIV immunocompromised hosts (transplant, hematologic malignancy, vasculitis on steroids), PCP often presents more acutely and with higher mortality.
Try two board-style Pneumocystis jirovecii Pneumonia questions
Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.
Question 1PulmonaryMedium
A 35-year-old man with HIV infection and a CD4 count of 65 cells/µL presents with one week of fever, progressive exertional dyspnea, and a nonproductive cough. He is on no prophylaxis, and his oxygen saturation falls with ambulation. Chest radiograph shows bilateral perihilar interstitial infiltrates, and serum lactate dehydrogenase (LDH) is markedly elevated. Which of the following is the most appropriate treatment?
ATrimethoprim-sulfamethoxazole
BCeftriaxone plus azithromycin
CValganciclovir hydrochloride
DAzithromycin and ethambutol
EAmphotericin B and flucytosine
Reveal answer & full explanation
Correct answer: A — Trimethoprim-sulfamethoxazole
ATrimethoprim-sulfamethoxazole✓
BCeftriaxone plus azithromycin
CValganciclovir hydrochloride
DAzithromycin and ethambutol
EAmphotericin B and flucytosine
Why Trimethoprim-sulfamethoxazole is correct
Advanced HIV (CD4 <200 cells/µL), subacute fever and nonproductive cough, exertional desaturation, bilateral perihilar/interstitial infiltrates, and a markedly elevated LDH are the classic picture of Pneumocystis jirovecii pneumonia (PCP).
High-dose trimethoprim-sulfamethoxazole (TMP-SMX) for 21 days is first-line therapy.
Adjunctive corticosteroids are added when room-air PaO₂ is <70 mmHg or the A-a gradient is ≥35 mmHg.
Why the others are wrong
Azithromycin and ethambutol — Part of a Mycobacterium avium complex regimen, which in AIDS presents as disseminated disease (weight loss, cytopenias, hepatosplenomegaly) rather than this interstitial pneumonitis; a buzzword trap for 'HIV plus cough.'
Ceftriaxone plus azithromycin — Empiric coverage for typical and atypical community-acquired pneumonia, which causes focal lobar consolidation and a productive cough rather than the diffuse interstitial pattern and high LDH seen here; a premature-closure trap.
Valganciclovir hydrochloride — Treats CMV disease, which in AIDS usually presents as retinitis or colitis rather than this LDH-driven interstitial pneumonitis; an anchoring trap on 'opportunistic infection.'
Amphotericin B and flucytosine — Pneumocystis jirovecii is classified as a fungus, so an antifungal regimen seems logical, but its cell membrane contains cholesterol rather than ergosterol, so amphotericin and the azoles are ineffective against it; amphotericin B plus flucytosine is induction therapy for cryptococcal meningitis, which presents with subacute headache and fever rather than this interstitial pneumonitis with a markedly elevated LDH; a classification trap on 'Pneumocystis is a fungus.'
Question 2Infectious DiseaseMedium
A 55-year-old male with newly diagnosed HIV (CD4 48, viral load 124,000, not on antiretroviral therapy) develops fever, dry cough, and progressive dyspnea over 3 weeks. CXR shows bilateral interstitial infiltrates. SpO2 90% on room air. Bronchoalveolar lavage with Gomori methenamine silver staining shows cysts and trophic forms of Pneumocystis jirovecii. LDH 680. PaO2 on room air 62 mmHg. Which of the following is the most appropriate treatment regimen?
ATrimethoprim-sulfamethoxazole plus corticosteroids
BGanciclovir plus foscarnet sodium therapy
CCeftriaxone plus azithromycin combination
DLiposomal amphotericin B plus flucytosine
EAtovaquone suspension plus corticosteroids
Reveal answer & full explanation
Correct answer: A — Trimethoprim-sulfamethoxazole plus corticosteroids
ATrimethoprim-sulfamethoxazole plus corticosteroids✓
BGanciclovir plus foscarnet sodium therapy
CCeftriaxone plus azithromycin combination
DLiposomal amphotericin B plus flucytosine
EAtovaquone suspension plus corticosteroids
Why Trimethoprim-sulfamethoxazole plus corticosteroids is correct
TMP-SMX 15-20 mg/kg/day (TMP component) in 3-4 divided doses for 21 days is first-line for Pneumocystis pneumonia (PCP)
This patient has moderate-severe disease (PaO2 below 70 mmHg on room air), so corticosteroids are mandatory, reducing mortality from 40% to 20%
Prednisone protocol: 40 mg BID x5 days, then 40 mg daily x5 days, then 20 mg daily x11 days
Corticosteroids blunt the vigorous inflammatory response triggered when organisms die during therapy
Why the others are wrong
Liposomal amphotericin B plus flucytosine — Treats cryptococcal and invasive fungal infection but has no activity against Pneumocystis jirovecii (right-concept-wrong-drug)
Ganciclovir plus foscarnet sodium therapy — Antivirals used for CMV, not appropriate for PCP (confused-with CMV)
Ceftriaxone plus azithromycin combination — Standard community-acquired pneumonia coverage with no activity against Pneumocystis (anchoring)
Atovaquone suspension plus corticosteroids — atovaquone is an oral PCP alternative and adjunctive corticosteroids fit his PaO2 below 70 mmHg, but atovaquone is less effective than TMP-SMX and is reserved for mild-moderate disease in patients who cannot take TMP-SMX; he has moderate-severe disease and no stated contraindication to first-line therapy (right-drug-wrong-severity)
Additional high-yield points
Alternatives for moderate-severe PCP (as here): IV pentamidine or primaquine plus IV clindamycin; dapsone plus trimethoprim and atovaquone are alternatives only for mild-moderate disease
Antiretroviral therapy: start within 2 weeks of PCP diagnosis (early ART lowers AIDS progression and death)
Prophylaxis: TMP-SMX double-strength daily when CD4 below 200
That's 2. Get 7,700+ more.
Unlock the full FirstPassPA bank: 7,700+ board-style questions, flashcards, and an AI tutor that explains every answer. Your 7-day free trial includes everything, and there's no credit card required.
You've read your 2 free diagnosis previews. Create your free account to unlock the full Pneumocystis jirovecii Pneumonia (PCP) outline — plus all 514 diagnoses, 7,700+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.
Malnutrition in infants and severely debilitated adults
Pathophysiology
Pneumocystis is acquired through inhalation and persists in human lungs; clinical disease results from defective cell-mediated immunity. Organisms adhere to type I pneumocytes, causing diffuse alveolar damage, foamy intra-alveolar exudate, and surfactant abnormalities. Inflammation and impaired gas exchange produce hypoxia disproportionate to chest x-ray findings.
Clinical presentation
Symptoms
HIV-associated: subacute progressive dyspnea, dry nonproductive cough, low-grade fever, fatigue, weight loss over weeks
Non-HIV immunocompromised: more abrupt onset (days), higher fevers, more severe hypoxia
Pleuritic chest pain is uncommon
Hemoptysis is uncommon
Asymptomatic carriage occurs
Signs / physical exam
Tachypnea, tachycardia
Hypoxia disproportionate to chest auscultation findings
Lung exam often surprisingly clear or with diffuse fine crackles
Oral thrush is common in HIV-associated disease
Exertional desaturation on ambulation is sensitive in early disease
Classic findings
HIV patient with CD4 <200, subacute dry cough, hypoxia disproportionate to a chest x-ray showing bilateral perihilar interstitial or ground-glass infiltrates. Markedly elevated LDH and beta-D-glucan.
Differential diagnosis
Bacterial pneumonia — Lobar consolidation, productive cough, leukocytosis; responds to standard antibiotics
Viral pneumonia (influenza, COVID-19, RSV, CMV in transplant) — Bilateral infiltrates, similar imaging; viral PCR, CMV PCR
Definitive diagnosis: identification of Pneumocystis by direct fluorescent antibody, GMS, Giemsa, or PCR on respiratory specimen. Presumptive treatment may be initiated based on clinical and radiographic picture in classic settings while awaiting confirmation.
Labs
ABG (or pulse oximetry with ambulation) — degree of hypoxia drives adjunctive steroid use
LDH (often markedly elevated)
Beta-D-glucan (sensitive but not specific)
HIV testing and CD4 count if not known
Induced sputum with silver stain (GMS), DFA, or PCR for Pneumocystis
Bronchoalveolar lavage (BAL) with PCR or staining if induced sputum negative or non-diagnostic — gold standard sensitivity
CBC, BMP, LFTs prior to TMP-SMX (renal function, baseline LFTs)
Imaging
Chest x-ray: bilateral perihilar reticular or ground-glass infiltrates; may be normal early in disease
Chest CT (more sensitive): diffuse ground-glass opacities with relative subpleural sparing, occasional cysts and pneumothorax
Findings of upper-lobe disease with pneumatoceles and pneumothorax classically associated with aerosolized pentamidine prophylaxis
Diagnostic algorithm
flowchart TD
A[Immunocompromised host<br/>HIV CD4 <200,<br/>steroids, transplant] --> B[Subacute dyspnea<br/>dry cough, hypoxia]
B --> C[CXR / CT: bilateral<br/>ground-glass infiltrates]
C --> D[LDH high, beta-D-glucan +]
D --> E[Induced sputum / BAL<br/>GMS, DFA, PCR]
E --> F[TMP-SMX x 21 days]
F --> G{PaO2 <70 or<br/>A-a >=35?}
G -->|Yes| H[Add prednisone taper<br/>40 BID x 5, 40 x 5, 20 x 11]
G -->|No| I[TMP-SMX alone]
F --> J[Secondary prophylaxis<br/>until CD4 >200 x 3 mo on ART]
PCP diagnostic and treatment pathway including adjunctive steroid indications.
Treatment
First-line
Trimethoprim-sulfamethoxazole (TMP-SMX) 15-20 mg/kg/day of TMP component IV or PO divided every 6-8 hours for 21 days — first-line for all severities
Adjunctive corticosteroids if PaO2 <70 mmHg on room air OR A-a gradient >=35 mmHg: prednisone 40 mg PO BID x 5 days, then 40 mg daily x 5 days, then 20 mg daily x 11 days (improves mortality in moderate to severe HIV-associated PCP)
Supportive care: supplemental oxygen, mechanical ventilation if needed
Initiate or continue antiretroviral therapy in HIV (no specific delay required for PCP, in contrast to cryptococcal meningitis)
Second-line / adjunct
Sulfa allergy or TMP-SMX intolerance — choose by severity:
Mild-moderate: dapsone-trimethoprim OR clindamycin-primaquine OR atovaquone
Severe: IV pentamidine 4 mg/kg/day or clindamycin-primaquine
G6PD testing prior to dapsone or primaquine (both cause hemolysis in G6PD deficiency)
Echinocandins (caspofungin) have weak activity and are NOT recommended as primary therapy
Secondary prophylaxis until CD4 >200 for >3 months on ART: TMP-SMX 1 single-strength or DS tablet daily; alternatives include dapsone, atovaquone, or aerosolized pentamidine
Drug toxicity from TMP-SMX: rash, fever, neutropenia, hyperkalemia, AKI, hepatitis
Treatment failure and mortality higher in non-HIV immunocompromised hosts
Immune reconstitution inflammatory syndrome (IRIS) if ART started concurrently — usually mild
PANCE pearls
TMP-SMX is the unambiguous first-line treatment AND prophylaxis for PCP at all severities — sulfa allergy must be carefully verified.
Adjunctive corticosteroids are mortality-reducing when PaO2 <70 mmHg or A-a gradient >=35 mmHg in HIV-associated PCP — do not forget to add them.
LDH and beta-D-glucan are useful supportive labs but neither establishes nor excludes diagnosis.
Primary PCP prophylaxis in HIV (NIH/HHS): TMP-SMX when CD4 <200 cells/microL in patients not yet on or just starting ART; once on ART, continue while CD4 <100, or 100-200 with a detectable viral load; stop when CD4 >=200 for >=3 months on ART.
Echinocandins (caspofungin) do not reliably treat PCP and should not be used as primary therapy.
TMP-SMX blocks two sequential steps of folate synthesis (sulfamethoxazole inhibits dihydropteroate synthase; trimethoprim inhibits dihydrofolate reductase); Pneumocystis membranes contain cholesterol rather than ergosterol, so amphotericin B and azoles do not work.
References
AIDSinfo / NIH / HHS — Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV — Pneumocystis jirovecii pneumonia section
CDC — CDC — Pneumocystis pneumonia: epidemiology, diagnosis, and treatment
ATS 2011 — An Official American Thoracic Society Statement: Treatment of Fungal Infections in Adult Pulmonary and Critical Care Patients (Limper et al., Am J Respir Crit Care Med 2011;183:96-128)
Practice Infectious Disease questions on FirstPassPA
Turn this outline into retention. 7,700+ board-style questions with an AI tutor that explains every answer — free to start, no card required.
Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.